Ken Griffin
STOK icon

Ken Griffin’s Stoke Therapeutics STOK Stock Holding History

Ken Griffin’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Buy
123,022
+107,171
+676% +$3.51M ﹤0.01% 4708
2025
Q4 		$503K Sell
15,851
-58,205
-79% -$1.75M ﹤0.01% 9003
2025
Q3 		$1.74M Sell
74,056
-29,188
-28% -$500K ﹤0.01% 6361
2025
Q2 		$1.17M Sell
103,244
-4,318
-4% -$41K ﹤0.01% 6734
2025
Q1 		$715K Buy
107,562
+14,982
+16% +$140K ﹤0.01% 7700
2024
Q4 		$1.02M Buy
92,580
+85,630
+1,232% +$1.05M ﹤0.01% 6967
2024
Q3 		$85.4K Buy
+6,950
New +$98.4K ﹤0.01% 11325
2024
Q1 		– Sell
-15,577
Closed -$94.4K – 15410
2023
Q4 		$81.9K Sell
15,577
-60,543
-80% -$259K ﹤0.01% 11190
2023
Q3 		$300K Sell
76,120
-96,178
-56% -$632K ﹤0.01% 9171
2023
Q2 		$1.83M Sell
172,298
-52,167
-23% -$555K ﹤0.01% 5299
2023
Q1 		$1.87M Sell
224,465
-85,041
-27% -$767K ﹤0.01% 5527
2022
Q4 		$2.86M Buy
309,506
+37,725
+14% +$392K ﹤0.01% 4834
2022
Q3 		$3.49M Buy
271,781
+146,544
+117% +$2.34M ﹤0.01% 4506
2022
Q2 		$1.65M Sell
125,237
-3,295
-3% -$50.1K ﹤0.01% 5940
2022
Q1 		$2.71M Buy
128,532
+120,110
+1,426% +$2.41M ﹤0.01% 5422
2021
Q4 		$202K Sell
8,422
-20,945
-71% -$500K ﹤0.01% 11835
2021
Q3 		$747K Sell
29,367
-29,765
-50% -$830K ﹤0.01% 8885
2021
Q2 		$1.99M Buy
59,132
+26,802
+83% +$947K ﹤0.01% 6634
2021
Q1 		$1.26M Buy
+32,330
New +$1.84M ﹤0.01% 7538
2020
Q2 		– Sell
-18,865
Closed -$432K – 10473
2020
Q1 		$432K Buy
18,865
+8,400
+80% +$208K ﹤0.01% 6711
2019
Q4 		$296K Buy
+10,465
New +$263K ﹤0.01% 7603
2019
Q3 		– Sell
-99,818
Closed -$2.91M – 9732
2019
Q2 		$2.91M Buy
+99,818
New +$2.68M ﹤0.01% 3906

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ken Griffin's STOK Position: Q1 2026 in Review

Ken Griffin increased its Stoke Therapeutics (STOK) stake by 676% in Q1 2026, buying an estimated $3.51M and bringing the position to 123,022 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4708.

Ken Griffin first reported a position in STOK in Q2 2019 and has held it in 22 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Ken Griffin held 123,022 shares of Stoke Therapeutics worth $4.01M as of Q1 2026.
  • Ken Griffin bought 107,171 Stoke Therapeutics shares in Q1 2026, an estimated $3.51M.
  • Stoke Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4708 holding.
  • Ken Griffin first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.